MOH Holdings Pte Ltd., Singapore, Singapore,
KK Women's and Children's Hospital, Singapore, Singapore,
Neuropsychobiology. 2019;78(1):1-6. doi: 10.1159/000498862. Epub 2019 Apr 4.
Derangements of the gut microbiome have been linked to increased systemic inflammation and central nervous system disorders, including schizophrenia. This systematic review thus aimed to investigate the hypothesis that probiotic supplementation improves schizophrenia symptoms.
By using the keywords (probiotic OR gut OR microbiota OR microbiome OR yogurt OR yoghurt OR lactobacillus OR bifidobacterium) AND (schizophrenia OR psychosis), a preliminary search of the PubMed, Medline, Embase, Google Scholar, ClinicalTrials.gov, Clinical Trials Register of the Cochrane Collaboration Depression, Anxiety and Neurosis Group (CCDANTR), and Cochrane Field for Complementary Medicine databases yielded 329 papers published in English between January 1, 1960 and May 1, 2018. Attempts were made to search grey literature as well.
Three clinical studies were reviewed, comparing the use of probiotics to placebo controls. Applying per-protocol analysis and a fixed-effects model, there was no significant difference in schizophrenia symptoms between the group that received probiotic supplementation and the placebo group post-intervention as the standardized mean difference was -0.0884 (95% CI -0.380 to 0.204, p = 0.551). Separate analyses were performed to investigate the effect of probiotic supplementation on positive or negative symptoms of schizophrenia alone. In both instances, no significant difference was observed as well.
Based on current evidence, limited inferences can be made regarding the efficacy of probiotics in schizophrenia. Although probiotics may have other benefits, for example to regulate bowel movement and ameliorate the metabolic effects of antipsychotic medications, the clinical utility of probiotics in the treatment of schizophrenia patients remains to be validated by future clinical studies.
肠道微生物群的紊乱与全身炎症和中枢神经系统疾病有关,包括精神分裂症。因此,本系统评价旨在调查益生菌补充剂是否能改善精神分裂症症状的假设。
使用关键词(益生菌或肠道或微生物群或微生物组或酸奶或酸奶或乳酸菌或双歧杆菌)和(精神分裂症或精神病),初步搜索 PubMed、Medline、Embase、Google Scholar、ClinicalTrials.gov、Cochrane 协作抑郁症、焦虑和神经症组(CCDANTR)临床试验登记处和 Cochrane 补充医学领域数据库,共检索到 1960 年 1 月 1 日至 2018 年 5 月 1 日期间以英文发表的 329 篇论文。还试图搜索灰色文献。
对 3 项临床研究进行了综述,比较了益生菌与安慰剂对照的使用。应用意向治疗分析和固定效应模型,干预后益生菌组和安慰剂组之间的精神分裂症症状无显著差异,标准化均数差为-0.0884(95%CI-0.380 至 0.204,p=0.551)。分别进行分析以研究益生菌补充对精神分裂症阳性或阴性症状的影响。在这两种情况下,也没有观察到显著差异。
基于目前的证据,可以对益生菌在精神分裂症中的疗效做出有限的推断。尽管益生菌可能有其他益处,例如调节肠道运动和改善抗精神病药物的代谢作用,但益生菌在精神分裂症患者治疗中的临床应用仍有待未来的临床研究验证。